Biosergen is preparing a Phase II study of BSG005 against Mucormycosis, the Black Fungus.
May 2, 2022: Biosergen today announced that it is preparing a Phase II clinical trial of BSG005 against Mucormycosis, otherwise known as the Black Fungus. Mucormycosis is a difficult to treat fungal infection with high mortality.As novel fungicidal polyene antifungal product BSG005 is well positioned to provide a broad single product treatment alternative for life threatening, difficult to treat, resistant, invasive fungal infections. Different to other polyene products, such as Amphotericin B or Ambisome, BSG005 is without any signs of nephrotoxicity. To support this unique product profile,